Skip to main content
Top
Published in: Journal of Gastroenterology 9/2012

01-09-2012 | Original Article—Liver, Pancreas, and Biliary Tract

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Authors: Nami Mori, Fumitaka Suzuki, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Masahiro Kobayashi, Satoshi Saito, Yoshiyuki Suzuki, Yasuji Arase, Kenji Ikeda, Mariko Kobayashi, Hiromitsu Kumada

Published in: Journal of Gastroenterology | Issue 9/2012

Login to get access

Abstract

Background

Severe acute exacerbation of chronic hepatitis B can sometimes occur and lead to hepatic failure and death. The objective of this study was to elucidate the predictors of progression to hepatic decompensation during severe acute exacerbation.

Methods

We prospectively analyzed 37 consecutive patients with acute exacerbation of chronic hepatitis B (accompanied by jaundice and coagulopathy) for clinical outcome and factors that influenced the development of severe acute exacerbation, including viral kinetics.

Results

Fourteen (37.8%) patients progressed to severe acute exacerbation (accompanied by encephalopathy). Multivariate analysis identified serum bilirubin (>5 mg/dl, P = 0.002) as a significant determinant of progression to hepatic failure and prothrombin activity (<45%, P = 0.028) and as a determinant of liver-related death. The hepatitis B virus (HBV) DNA level before therapy was measured in 25 patients. HBV DNA levels increased or did not change from before commencement of treatment in all 11 patients who progressed to severe acute exacerbation. On the other hand, HBV DNA levels did not change or increased in 8 of 14 patients (57%) with acute exacerbation (P = 0.02).

Conclusions

Serum bilirubin and prothrombin activities were significant predictors of clinical outcome in patients with severe acute exacerbation of chronic hepatitis B. Viral kinetics until commencement of therapy can predict the severity of acute exacerbation of chronic hepatitis B.
Literature
1.
go back to reference Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–33.PubMedCrossRef Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan. Lancet. 1981;2:1129–33.PubMedCrossRef
2.
go back to reference Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.PubMedCrossRef Hsu YS, Chien RN, Yeh CT, Sheen IS, Chiou HY, Chu CM, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522–7.PubMedCrossRef
3.
go back to reference Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732–5.PubMed Sheen IS, Liaw YF, Tai DI, Chu CM. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis. Gastroenterology. 1985;89:732–5.PubMed
4.
go back to reference Chu CM, Liaw YF. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection. 2005;33:136–9.PubMedCrossRef Chu CM, Liaw YF. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection. 2005;33:136–9.PubMedCrossRef
5.
go back to reference Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology. 1990;12:570–4.PubMedCrossRef Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology. 1990;12:570–4.PubMedCrossRef
6.
go back to reference Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230–5.PubMed Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984;86:230–5.PubMed
7.
go back to reference Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.PubMed Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.PubMed
8.
go back to reference Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.PubMedCrossRef Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.PubMedCrossRef
9.
go back to reference Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426–32.PubMedCrossRef Tsubota A, Arase Y, Suzuki Y, Suzuki F, Sezaki H, Hosaka T, et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol. 2005;20:426–32.PubMedCrossRef
10.
go back to reference Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011;54:236–42.PubMedCrossRef Wong VW, Wong GL, Yiu KK, Chim AM, Chu SH, Chan HY, et al. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. J Hepatol. 2011;54:236–42.PubMedCrossRef
11.
go back to reference Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.PubMedCrossRef Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure. Hepatology. 2011;53:774–80.PubMedCrossRef
12.
go back to reference Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003;36:979–84.PubMedCrossRef Yuen MF, Sablon E, Hui CK, Li TM, Yuan HJ, Wong DK, et al. Prognostic factors in severe exacerbation of chronic hepatitis B. Clin Infect Dis. 2003;36:979–84.PubMedCrossRef
13.
go back to reference Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8:541–5.PubMedCrossRef Jeng WJ, Sheen IS, Liaw YF. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol. 2010;8:541–5.PubMedCrossRef
14.
go back to reference Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S. Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–57.PubMedCrossRef Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S. Intractable Liver Diseases Study Group of Japan. Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 2008;38:646–57.PubMedCrossRef
15.
go back to reference Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res. 2008;38(The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28–29 September 2007, Iwate, Japan):S52–5. Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatol Res. 2008;38(The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28–29 September 2007, Iwate, Japan):S52–5.
16.
go back to reference Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology. 1987;7:582–5.PubMedCrossRef Sjogren MH, Hoofnagle JH, Waggoner JG. Effect of corticosteroid therapy on levels of antibody to hepatitis B core antigen in patients with chronic type B hepatitis. Hepatology. 1987;7:582–5.PubMedCrossRef
17.
go back to reference European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRef European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–42.CrossRef
19.
go back to reference Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;22:262–83. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;22:262–83.
20.
go back to reference Tsubota A, Arase Y, Suzuki Y, Suzuki F, Hosaka T, Someya T, et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology. 2004;47:335–41.PubMedCrossRef Tsubota A, Arase Y, Suzuki Y, Suzuki F, Hosaka T, Someya T, et al. Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection. Intervirology. 2004;47:335–41.PubMedCrossRef
21.
go back to reference Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–7.PubMedCrossRef Chien RN, Lin CH, Liaw YF. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol. 2003;38:322–7.PubMedCrossRef
22.
go back to reference Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711–9.PubMedCrossRef Fujiwara K, Yasui S, Yonemitsu Y, Fukai K, Arai M, Imazeki F, et al. Efficacy of combination therapy of antiviral and immunosuppressive drugs for the treatment of severe acute exacerbation of chronic hepatitis B. J Gastroenterol. 2008;43:711–9.PubMedCrossRef
23.
go back to reference Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J Virol Method. 1999;80:97–112.CrossRef Usuda S, Okamoto H, Imawari H, Baba K, Tsuda F, Miyakawa Y, et al. Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in preS2-region product. J Virol Method. 1999;80:97–112.CrossRef
24.
go back to reference Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Method. 2006;138:30–9.CrossRef Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes. J Virol Method. 2006;138:30–9.CrossRef
25.
go back to reference Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, et al. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol. 2002;97:2629–33.PubMedCrossRef Chan HL, Tsang SW, Wong ML, Tse CH, Leung NW, Chan FK, et al. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol. 2002;97:2629–33.PubMedCrossRef
26.
go back to reference Kobayashi M, Ikeda K, Arase Y, Suzuki F, Akuta N, Hosaka T, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol. 2008;80:1880–4.PubMedCrossRef Kobayashi M, Ikeda K, Arase Y, Suzuki F, Akuta N, Hosaka T, et al. Change of hepatitis B virus genotypes in acute and chronic infections in Japan. J Med Virol. 2008;80:1880–4.PubMedCrossRef
27.
go back to reference Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003;52:1630–7.PubMedCrossRef Imamura T, Yokosuka O, Kurihara T, Kanda T, Fukai K, Imazeki F, et al. Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut. 2003;52:1630–7.PubMedCrossRef
28.
go back to reference Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, et al. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin Infect Dis. 2003;37:593–7.PubMedCrossRef Yuen MF, Sablon E, Wong DK, Yuan HJ, Wong BC, Chan AO, et al. Role of hepatitis B virus genotypes in chronic hepatitis B exacerbation. Clin Infect Dis. 2003;37:593–7.PubMedCrossRef
29.
go back to reference Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006;44:326–34.PubMedCrossRef Ozasa A, Tanaka Y, Orito E, Sugiyama M, Kang JH, Hige S, et al. Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology. 2006;44:326–34.PubMedCrossRef
30.
go back to reference Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996;98:2268–76.PubMedCrossRef Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest. 1996;98:2268–76.PubMedCrossRef
31.
go back to reference Ren EX, Xu Z, Liu Y, Li X, Bai S, Ding N, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat. 2010;17:887–95.PubMedCrossRef Ren EX, Xu Z, Liu Y, Li X, Bai S, Ding N, et al. Hepatitis B virus genotype and basal core promoter/precore mutations are associated with hepatitis B-related acute-on-chronic liver failure without pre-existing liver cirrhosis. J Viral Hepat. 2010;17:887–95.PubMedCrossRef
32.
go back to reference Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with epidemic of fulminant hepatitis. N Engl J Med. 1991;324:175–9.CrossRef Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with epidemic of fulminant hepatitis. N Engl J Med. 1991;324:175–9.CrossRef
33.
go back to reference Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol. 1992;66:4073–84.PubMed Yuh CH, Chang YL, Ting LP. Transcriptional regulation of precore and pregenomic RNAs of hepatitis B virus. J Virol. 1992;66:4073–84.PubMed
34.
go back to reference Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–22.PubMedCrossRef Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology. 2001;120:1009–22.PubMedCrossRef
35.
go back to reference Higuchi N, Kato M, Kotoh K, Kojima M, Aishima S, Nakamuta M, et al. Methylprednisolone injection via the potal vein suppresses inflammation in acute liver failure induced in rats by lipopolysaccharide and d-galactosamine. Liver Int. 2007;27:1342–8.PubMedCrossRef Higuchi N, Kato M, Kotoh K, Kojima M, Aishima S, Nakamuta M, et al. Methylprednisolone injection via the potal vein suppresses inflammation in acute liver failure induced in rats by lipopolysaccharide and d-galactosamine. Liver Int. 2007;27:1342–8.PubMedCrossRef
36.
go back to reference Wang M, Shen F, Shi LH, Xi T, Li XF, Chen X, et al. Protective effect of prednisolone on ischemia-induced liver injury in rats. World J Gastroenterol. 2008;14:4332–7.PubMedCrossRef Wang M, Shen F, Shi LH, Xi T, Li XF, Chen X, et al. Protective effect of prednisolone on ischemia-induced liver injury in rats. World J Gastroenterol. 2008;14:4332–7.PubMedCrossRef
37.
go back to reference Dich J, Vind C, Grunnet N. Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity. Hepatology. 1998;8:39–45.CrossRef Dich J, Vind C, Grunnet N. Long-term culture of hepatocytes: effect of hormones on enzyme activities and metabolic capacity. Hepatology. 1998;8:39–45.CrossRef
38.
go back to reference Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707–19.PubMedCrossRef Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol. 2004;78:5707–19.PubMedCrossRef
39.
go back to reference Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–80.PubMedCrossRef Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus infection. J Exp Med. 2000;191:1269–80.PubMedCrossRef
40.
go back to reference Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology. 1998;115:177–81.PubMedCrossRef Chan TM, Wu PC, Li FK, Lai CL, Cheng IKP, Lai KN. Treatment of fibrosing cholestatic hepatitis with lamivudine. Gastroenterology. 1998;115:177–81.PubMedCrossRef
41.
go back to reference Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46–53.PubMedCrossRef Zhang XQ, Jiang L, You JP, Liu YY, Peng J, Zhang HY, et al. Efficacy of short-term dexamethasone therapy in acute-on-chronic pre-liver failure. Hepatol Res. 2011;41:46–53.PubMedCrossRef
Metadata
Title
Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection
Authors
Nami Mori
Fumitaka Suzuki
Yusuke Kawamura
Hitomi Sezaki
Tetsuya Hosaka
Norio Akuta
Masahiro Kobayashi
Satoshi Saito
Yoshiyuki Suzuki
Yasuji Arase
Kenji Ikeda
Mariko Kobayashi
Hiromitsu Kumada
Publication date
01-09-2012
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2012
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0561-8

Other articles of this Issue 9/2012

Journal of Gastroenterology 9/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.